<DOC>
	<DOC>NCT02652234</DOC>
	<brief_summary>This is an open-label, single-arm study to assess the safety, tolerability and pharmacokinetics of Endostar subcutaneous injection in Chinese advanced NSCLC patients.</brief_summary>
	<brief_title>Study of Endostar Subcutaneous Injection in NSCLC</brief_title>
	<detailed_description />
	<criteria>Histological/cytological confirmed unresectable stage ⅢB～Ⅳ nonsquamous NSCLC ECOG performance status 01 Life expectancy≥3 months Adequate hematologic function: WBC≥3.0×109/L ,ANC≥1.5×10^9/L, Hb≥90g/L, PLT≥100×10^9/L; Adequate hepatic and renal function: ALT≤2.5×ULN, AST≤2.5×ULN, TBIL≤1.5×ULN, creatinine≤1×ULN, creatinine clearance≥50ml/min; Normal coagulation function (PT, APTT, TT, Fbg) ; Patients signed informed consent form; Willingness and capability to comply with protocol requirement and well communicate with investigators. With uncontrolled ascites or pleural effusion; Patients receiving a chest or abdominal surgery within 28 days before enrollment; or with not fully healed surgical incision; or expected to receive surgery during the study; History of ischemic or TIA within 6 months before enrollment; Uncontrolled hypertension, hypertensive crisis or hypertensive encephalopathy; Arrhythmias need to be treated; history of coronary artery disease (including angina pectoris and myocardial infarction) or ischemic myocardium; congestive heartfailure NYHA class ≥ II； Serious active infections; History of abdominal fistula, gastrointestinal perforation, abdominal abscess within 6 months prior to enrollment; Symptomatic brain or meningeal metastasis; Epileptic seizure need to be treated; HCV, HBV or HIV positive; History of other malignant tumors within 5 years (except curable cervix carcinoma in situ or skin basal cell carcinoma); Known allergies to any excipient in the study drug; Any conditions that may interfere with the patient's participation in the study or have an impact on the assessment of the results of the study; Any conditions that may endanger patient safety or interfere with the patient's compliance; Pregnant and lactating women; The investigators consider the patients unsuitable for this trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>